mrna-encoded anti-cd3/anti-cldn6 bispecific antibody bnt142
Generic: mRNA-encoded Anti-CD3/Anti-CLDN6 Bispecific Antibody BNT142
mrna-encoded anti-cd3/anti-cldn6 bispecific antibody bnt142: 1 clinical trial tracked.
mrna-encoded anti-cd3/anti-cldn6 bispecific antibody bnt142 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about mrna-encoded anti-cd3/anti-cldn6 bispecific antibody bnt142, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
First-in-human, Open-label, Multicenter, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT142 in Patients With CLDN6-positive Advanced Solid Tumors
Primary endpoint: Occurrence of treatment emergent adverse events (TEAEs) including Grade ≥3, serious, or fatal TEAEs by causal relationship to study treatment
Interventionalopen73 targetStarted 2022-03Completion 2025-1218 sites · Singapore, Spain, United Kingdom, United StatesBioNTech SE